Dianthus Therapeutics (DNTH) EVP Simrat Randhawa Exercises Options & Sells Shares

What Happened

• Simrat Randhawa, EVP & Head of R&D at Dianthus Therapeutics (DNTH), exercised stock options to acquire a total of 23,124 shares on 2026-09-01 (exercise cost ≈ $477,047) and then disposed of the same 23,124 shares in open-market sales for total proceeds of approximately $2,460,691. The exercises and sales were reported on a Form 4 filed 2026-09-03.
• These transactions represent an option exercise followed by immediate sale (i.e., effectively a cashless conversion and sale). The sales were executed pursuant to a Rule 10b5-1 trading plan adopted August 14, 2025, which typically indicates pre-arranged, scheduled sales rather than discretionary trading.

Key Details

• Transaction date: September 1, 2026.
• Options exercised: 7,500 shares @ $17.88 ($134,100); 6,249 shares @ $21.77 ($136,041); 9,375 shares @ $22.07 ($206,906). Total exercise cost ≈ $477,047.
• Open-market sales (same-day): 2,600 shares @ weighted avg $105.19 (proceeds $273,494; prices ranged $104.50–$105.46); 7,215 shares @ weighted avg $106.25 (proceeds $766,594; prices ranged $105.53–$106.52); 13,309 shares @ weighted avg $106.74 (proceeds $1,420,603; prices ranged $106.53–$107.31). Total proceeds ≈ $2,460,691.
• Net proceeds (sales minus exercise cost) ≈ $1,983,644.
• Shares owned after transaction: not disclosed in the provided filing details.
• Notable footnotes: F1 — sales executed under a Rule 10b5‑1 plan (adopted Aug 14, 2025). F2–F4 — reported sale prices are weighted averages across multiple executions (ranges provided). F5–F7 — referenced option awards vest monthly over four years from various grant start dates (Jan 1, 2024; May 1, 2024; Jan 1, 2025).
• Filing timeliness: Form 4 was filed on 2026-09-03 for 2026-09-01 transactions; filing appears timely.

Context

• For retail investors: this is a common pattern where an insider exercises vested options and immediately sells the resulting shares (cashless exercise). Because the sales were done under a pre-established 10b5‑1 plan, they are generally considered scheduled transactions and should not be read as a discretionary signal of changing sentiment.
• The Form shows separate derivative "disposed @ $0" entries consistent with conversion/surrender mechanics tied to the exercise; the meaningful economic events are the option exercise (cost paid) and the open‑market sales (proceeds).